Welcome to our dedicated page for Ventyx Biosciences news (Ticker: VTYX), a resource for investors and traders seeking the latest updates and insights on Ventyx Biosciences stock.
Ventyx Biosciences, Inc. (VTYX) is a clinical-stage biopharmaceutical company developing novel oral therapies for inflammatory diseases, autoimmune disorders, and neurodegenerative conditions. This page provides investors and researchers with centralized access to official announcements, clinical trial updates, and strategic developments.
Track the progress of Ventyx's diversified pipeline including its selective TYK2 inhibitor program and NLRP3 inflammasome-targeted therapies. Stay informed about regulatory milestones, partnership announcements, and scientific presentations through verified press releases and curated news coverage.
Key updates include clinical trial results, R&D advancements, and business developments related to the company's focus on precision-targeted small molecules. All content is sourced directly from company filings and reputable industry publications to ensure reliability.
Bookmark this page for streamlined access to essential VTYX updates. For comprehensive analysis of Ventyx Biosciences' therapeutic pipeline and market position, consult our full company profile and regulatory filings database.
Ventyx Biosciences (NASDAQ: VTYX) has expanded its Scientific Advisory Board (SAB) with seven internationally-recognized experts specializing in NLRP3 inflammasome and neurodegenerative diseases. The new appointments include Mo Lamkanfi, Luke O'Neill, Ted Dawson, Martin Pomper, Antonio Abbate, Paul Cremer, and Don Frail.
The expansion validates Ventyx's leadership in NLRP3 inflammasome chemistry and biology. The company is currently progressing two oral NLRP3 inhibitors through Phase 2 studies in Parkinson's disease, cardiometabolic disease, and recurrent pericarditis. Notably, topline data from the Phase 2 study of VTX3232, their CNS-penetrant NLRP3 inhibitor for Parkinson's disease, is expected in Q2 2025.
Ventyx Biosciences (VTYX) reported its Q4 and full year 2024 financial results, highlighting multiple upcoming Phase 2 data readouts in 2025. The company maintains a strong financial position with $252.9 million in cash and equivalents, expected to fund operations into H2 2026.
Key pipeline updates include:
- VTX2735 Phase 2 trial in recurrent pericarditis results expected in H2 2025
- VTX3232 Phase 2 trial in obesity and cardiometabolic risk factors data expected in H2 2025
- VTX3232 biomarker study in early Parkinson's disease completion expected in Q2 2025
Financial highlights for 2024:
- R&D expenses decreased to $117.0M from $175.8M in 2023
- G&A expenses slightly decreased to $31.4M from $32.2M in 2023
- Net loss improved to $135.1M compared to $193.0M in 2023
Ventyx Biosciences (VTYX) announced Phase 2 trial results for VTX958, its TYK2 inhibitor for Crohn's disease. While the trial did not meet its primary endpoint of change in Crohn's Disease Activity Index (CDAI), likely due to high placebo response, it demonstrated significant endoscopic improvements. The study showed dose-dependent endoscopic response rates of 24.3% for 225mg and 32.4% for 300mg doses, compared to 5.7% for placebo at Week 12.
The trial involved 109 subjects randomized across placebo and two VTX958 dosage groups (225mg and 300mg BID) for a 12-week induction period, followed by a 40-week maintenance phase. Notable results included significant reductions in SES-CD scores for both dosage groups compared to placebo, and improved clinical-biomarker response rates (43.2% for 300mg vs 14.3% for placebo). The company is analyzing full 52-week data to inform future development strategy and partnership opportunities.
Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company specializing in innovative oral therapies for autoimmune, inflammatory, and neurodegenerative diseases, has announced its participation in the upcoming Oppenheimer 35th Annual Healthcare Life Sciences Conference.
The virtual event is scheduled for Wednesday, February 12, 2025, from 2:40-3:10 PM ET. The company will provide a presentation, which will be accessible via webcast through the Investors and News section of Ventyx's website at www.ventyxbio.com. A replay of the presentation will remain available on the website for ninety days following the event.
Ventyx Biosciences (NASDAQ: VTYX) has outlined its 2025 pipeline strategy, focusing on its NLRP3 inhibitor portfolio. The company has initiated three significant Phase 2 trials: VTX3232 for obesity and cardiometabolic risk factors (topline data expected H2 2025), VTX2735 for recurrent pericarditis (starting January, topline data H2 2025), and VTX3232 for early Parkinson's disease (topline data H1 2025).
The company reported $252.9M in cash and equivalents as of December 31, 2024, expected to fund operations into H2 2026. Regarding their IBD portfolio, they are exploring partnership opportunities for tamuzimod in ulcerative colitis, while analyzing Phase 2 data for VTX958 in Crohn's disease to inform future development strategy.
Ventyx Biosciences (Nasdaq: VTYX), a clinical-stage biopharmaceutical company developing oral therapies for inflammatory diseases, has announced its participation in three major investor conferences. The company will present at the Stifel 2024 Healthcare Conference in New York on November 18, the Jefferies London Healthcare Conference on November 20, and the Piper Sandler Healthcare Conference in New York on December 4. Webcasts of all presentations will be available on the company's website for thirty days following each event.
Ventyx Biosciences (VTYX) reported Q3 2024 financial results and pipeline updates. The company maintains a strong cash position of $274.8 million, expected to fund operations into H2 2026. Net loss decreased to $35.2 million from $54.0 million in Q3 2023, while R&D expenses reduced to $30.6 million from $49.8 million.
Key pipeline developments include planned Phase 2 trials for VTX2735 in recurrent pericarditis and VTX3232 in obesity, both expected to initiate by year-end. Topline results from VTX3232's Phase 2a trial in early Parkinson's disease are anticipated in H1 2025. The company seeks partnership for tamuzimod's Phase 3 trial in ulcerative colitis.
Ventyx Biosciences (Nasdaq: VTYX) presented new 52-week results from the Phase 2 trial of VTX002 (tamuzimod) in ulcerative colitis at UEG Week 2024. The late-breaking abstract highlighted high rates of clinical and endoscopic remission among long-term extension (LTE) completers at Week 52. CEO Raju Mohan emphasized the data's reinforcement of tamuzimod's potential best-in-class profile as an S1P1R modulator in ulcerative colitis, with a possibly best-in-disease safety profile among oral UC therapies. The company believes these results position tamuzimod as the backbone of future combination therapies for UC. The presentation, delivered by Dr. Silvio Danese, focused on the efficacy and safety of tamuzimod through 52 weeks in moderately to severely active ulcerative colitis.
Ventyx Biosciences (Nasdaq: VTYX) announced a $27 million strategic investment from Sanofi. Sanofi will purchase 70,601 shares of Ventyx's Series A non-voting convertible preferred stock at $3.8243 per share, convertible into 100 shares of common stock each. The transaction is expected to close on September 23, 2024.
As part of the deal, Sanofi receives an exclusive right of first negotiation for Ventyx's CNS-penetrant NLRP3 inhibitor VTX3232. Ventyx CEO Raju Mohan expressed optimism about the investment, highlighting Sanofi's leadership in immunological and inflammatory diseases. The company expects data from VTX3232's Phase 2a trial in early Parkinson's disease and Phase 2 trial in obesity with cardiometabolic risk factors in 2025.
The investment is expected to strengthen Ventyx's cash position, with current resources projected to fund operations into at least the second half of 2026.
Ventyx Biosciences (Nasdaq: VTYX) has initiated dosing in a Phase 2a trial of VTX3232 for early Parkinson's disease. The trial aims to evaluate the drug's effects on disease- and target-relevant biomarkers, including exploratory PET neuroimaging to measure its impact on microglial activation. This study is based on evidence suggesting a strong mechanistic rationale for targeting NLRP3-driven neuroinflammation in Parkinson's disease.
The trial will enroll about ten patients for a 28-day open-label treatment period. Its primary endpoint is safety and tolerability, with additional measures including pharmacokinetics and relevant biomarkers in plasma and cerebrospinal fluid. Topline results are expected in 2025.
